Chemical formula: C₄₀H₅₉NO₁₁ Molecular mass: 729.908 g/mol PubChem compound: 73425383
Eribulin mesylate is indicated for:
Population group: only adults (18 - 65 years old)
Eribulin is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 - 65 years old)
Eribulin is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Eribulin mesylate is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
